These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 15718319)
1. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. Voit C; Kron M; Rademaker J; Schwürzer-Voit M; Sterry W; Weber L; Ozdemir C; Proebstle T; Keilholz U J Clin Oncol; 2005 Feb; 23(6):1218-27. PubMed ID: 15718319 [TBL] [Abstract][Full Text] [Related]
2. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977 [TBL] [Abstract][Full Text] [Related]
3. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789 [TBL] [Abstract][Full Text] [Related]
4. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783 [TBL] [Abstract][Full Text] [Related]
5. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients. Kammula US; Ghossein R; Bhattacharya S; Coit DG J Clin Oncol; 2004 Oct; 22(19):3989-96. PubMed ID: 15459222 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients. Mangas C; Hilari JM; Paradelo C; Rex J; Fernández-Figueras MT; Fraile M; Alastrue A; Ferrándiz C Ann Surg Oncol; 2006 Jul; 13(7):910-8. PubMed ID: 16788751 [TBL] [Abstract][Full Text] [Related]
7. Detection of tyrosinase mRNA from the blood of melanoma patients. Stevens GL; Scheer WD; Levine EA Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tyrosinase mRNA detected by nested RT-PCR in patients with malignant melanoma. Glumac N; Snoj M; Hocevar M; Novakovic S Neoplasma; 2006; 53(1):9-14. PubMed ID: 16416006 [TBL] [Abstract][Full Text] [Related]
9. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308 [TBL] [Abstract][Full Text] [Related]
10. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Aubin F; Chtourou M; Teyssier JR; Laubriet A; Mougin CH; Blanc D; Humbert P Melanoma Res; 2000 Apr; 10(2):113-8. PubMed ID: 10803711 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Mellado B; Gutierrez L; Castel T; Colomer D; Fontanillas M; Castro J; Estapé J Clin Cancer Res; 1999 Jul; 5(7):1843-8. PubMed ID: 10430090 [TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Ghossein RA; Coit D; Brennan M; Zhang ZF; Wang Y; Bhattacharya S; Houghton A; Rosai J Clin Cancer Res; 1998 Feb; 4(2):419-28. PubMed ID: 9516931 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991 [TBL] [Abstract][Full Text] [Related]
15. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676 [TBL] [Abstract][Full Text] [Related]
16. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay. Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828 [TBL] [Abstract][Full Text] [Related]
18. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases. Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396 [TBL] [Abstract][Full Text] [Related]
19. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670 [TBL] [Abstract][Full Text] [Related]
20. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Hoon DS; Bostick P; Kuo C; Okamoto T; Wang HJ; Elashoff R; Morton DL Cancer Res; 2000 Apr; 60(8):2253-7. PubMed ID: 10786692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]